Natera (NASDAQ:NTRA – Get Rating) was upgraded by equities research analysts at StockNews.com to a "sell" rating in a research note issued on Thursday.

NTRA has been the subject of several other research reports. JPMorgan Chase & Co. boosted their price target on Natera from $80.00 to $100.00 in a research note on Friday, August 5th. Stephens initiated coverage on Natera in a research report on Monday, April 25th. They set an "overweight" rating and a $54.00 price objective for the company. Cowen reduced their price objective on Natera from $110.00 to $100.00 in a research report on Friday, May 6th. Robert W. Baird reduced their price objective on Natera from $100.00 to $71.00 in a research report on Friday, May 6th. Finally, Cowen reduced their price objective on Natera from $110.00 to $100.00 in a research report on Friday, May 6th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $93.18.

Natera Trading Up 2.9 %

NTRA stock opened at $55.17 on Thursday. Natera has a 1-year low of $26.10 and a 1-year high of $129.09. The business has a fifty day moving average price of $41.80 and a 200-day moving average price of $45.10. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.13 and a current ratio of 3.58.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 1,652 shares of the business's stock in a transaction dated Thursday, June 23rd. The stock was sold at an average price of $35.76, for a total transaction of $59,075.52. Following the completion of the sale, the chief executive officer now owns 64,777 shares of the company's stock, valued at $2,316,425.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Steven Leonard Chapman sold 1,652 shares of the company's stock in a transaction dated Thursday, June 23rd. The stock was sold at an average price of $35.76, for a total value of $59,075.52. Following the completion of the transaction, the chief executive officer now owns 64,777 shares of the company's stock, valued at $2,316,425.52. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Daniel Rabinowitz sold 689 shares of the company's stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $39.02, for a total value of $26,884.78. Following the completion of the transaction, the insider now directly owns 144,478 shares of the company's stock, valued at approximately $5,637,531.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,966 shares of company stock valued at $550,755. Company insiders own 10.27% of the company's stock.

Hedge Funds Weigh In On Natera

Hedge funds have recently made changes to their positions in the business. CENTRAL TRUST Co boosted its stake in shares of Natera by 200.0% in the fourth quarter. CENTRAL TRUST Co now owns 300 shares of the medical research company's stock worth $28,000 after acquiring an additional 200 shares during the period. CWM LLC boosted its stake in shares of Natera by 1,041.0% in the first quarter. CWM LLC now owns 696 shares of the medical research company's stock worth $28,000 after acquiring an additional 635 shares during the period. Parallel Advisors LLC lifted its position in shares of Natera by 84.2% in the second quarter. Parallel Advisors LLC now owns 829 shares of the medical research company's stock worth $29,000 after buying an additional 379 shares in the last quarter. Industrial Alliance Investment Management Inc. purchased a new stake in shares of Natera in the fourth quarter worth about $30,000. Finally, Industry Ventures L.L.C. purchased a new stake in shares of Natera in the fourth quarter worth about $30,000. Institutional investors own 96.24% of the company's stock.

About Natera

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also

• Get a free copy of the StockNews.com research report on Natera (NTRA)
• MarketBeat: Week in Review 8/8 – 8/12
• 2 Important Retail Stock Battles to Watch
• What Is WallStreetBets and What Stocks Are They Targeting?
• Institutions And Analysts Propel Jack In The Box Higher
• Can You Guess Which EV Stock Is Beating Tesla ?

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.